Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Update

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the recipient of a large drop in short interest during the month of March. As of March 13th, there was short interest totaling 12,316 shares, a drop of 14.0% from the February 26th total of 14,323 shares. Based on an average daily volume of 86,687 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the shares of the company are short sold.

Institutional Investors Weigh In On Neuphoria Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Commonwealth Equity Services LLC purchased a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth $43,000. XTX Topco Ltd purchased a new position in shares of Neuphoria Therapeutics in the fourth quarter valued at $47,000. Persistent Asset Partners Ltd grew its position in shares of Neuphoria Therapeutics by 173.1% in the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after purchasing an additional 8,495 shares in the last quarter. Boothbay Fund Management LLC bought a new stake in shares of Neuphoria Therapeutics during the 4th quarter valued at $54,000. Finally, Bridgeway Capital Management LLC purchased a new stake in Neuphoria Therapeutics during the 4th quarter worth about $57,000. Institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Stock Performance

NASDAQ NEUP traded up $0.24 during trading on Tuesday, hitting $4.18. 24,158 shares of the company’s stock traded hands, compared to its average volume of 47,983. The stock has a market capitalization of $22.53 million, a price-to-earnings ratio of -0.95 and a beta of 0.50. Neuphoria Therapeutics has a 12-month low of $3.64 and a 12-month high of $21.40. The business has a 50 day moving average of $4.27 and a 200-day moving average of $6.18.

Neuphoria Therapeutics (NASDAQ:NEUP) last posted its earnings results on Tuesday, February 17th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.21). On average, analysts expect that Neuphoria Therapeutics will post -1.56 EPS for the current year.

Analysts Set New Price Targets

NEUP has been the topic of a number of research analyst reports. Zacks Research raised shares of Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. HC Wainwright lowered their price objective on shares of Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, December 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $21.00.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.